Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03080116
Recruitment Status : Recruiting
First Posted : March 15, 2017
Last Update Posted : December 24, 2020
Sponsor:
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:

RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination.

PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.


Condition or disease Intervention/treatment Phase
Prostate Cancer Neoadjuvant Therapy Androgen Antagonists Prostatectomy Drug: ARN-509 Drug: Degarelix Other: Placebo Phase 2

Detailed Description:

PRIMARY OBJECTIVE: To assess the difference in antitumor effect between the treatment arms by measuring MRD following radical prostatectomy.

SECONDARY OBJECTIVES: To measure differences between study arms in

  • Proportions of post neoadjuvant prostate specific antigen (PSA) ≤ 0.3 ng/ml as a predictor of prostate cancer mortality
  • T down-staging, complete pathological response, PSA kinetics, Testosterone kinetics, operation time, blood loss, grade of surgical difficulty
  • New generation hybrid imaging 68Ga PSMA (Prostate-Specific Membrane Antigen) PET/MR (Positron emission tomography/Magnetic Resonance) derived parameters
  • Early biochemical recurrence as prognostic factor of prostate cancer mortality
  • Transcriptome and genome
  • Tissue microarrays (TMA) protein expression (DNA repair, resistance etc.) by immunohistochemistry
  • Perioperative safety and tolerability
  • Quality of life, erection recovery, continence through validated preoperative and postoperative questionnaires pre and postop (IEEF5, ICIQ, EORTC QLQ-C30)

OUTLINE: interventional, single center, phase II, randomized, double blind, placebo controlled trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial
Actual Study Start Date : March 28, 2019
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : December 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ARN-509 + degarelix
Treatment period of 12 weeks before RP + PLND.
Drug: ARN-509
240mg/day (4x60mg tablets, Oral administration: OS)
Other Name: apalutamide

Drug: Degarelix
1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Active Comparator: placebo + degarelix
Treatment period of 12 weeks before RP + PLND.
Drug: Degarelix
1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly

Other: Placebo
4 tablets, per OS




Primary Outcome Measures :
  1. Minimal Residual Disease (MRD) [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Proportions of MRD between arms. MRD: tumor volume ≤ 0.25 cm3


Secondary Outcome Measures :
  1. Difference in proportions of pathological downstage [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Any decrease in T stage from clinical to pathological stage

  2. Complete pathological response rates [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Difference in proportions of complete pathological response (no evidence of tumour in the postoperative specimen) between arms.

  3. Difference in proportions of patients with pN1 disease. [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Difference in proportions of lymph node invasion between arms

  4. Proteins expression in prostatic tumour TMA's (tissue microarrays) [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Intensity of immunoreactivity and percentage of immunoreactive cells for, selected markers between arms. The TMA's will be produced from the formalin-fixed paraffin-embedded (FFPE) specimen of the RP.

  5. Transcriptome analysis by microarray expression platform [ Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND ]
    To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens: clinical-grade high-density oligonucleotide microarray expression platform and cloud-based informatics pipeline to interrogate 1.4M probe sets representing all known ~46K genes and non-coding RNAs.

  6. Pathway profiling and Gene Set Enrichment Analyses [ Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND ]
    To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens. Pathway profiling and Gene Set Enrichment Analyses will also be used to generate pathway scores for the 'androgen receptor signaling pathway'; determination of pathway scores for the DNA damage checkpoints and the different DNA repair pathways.

  7. Genomic subtyping by exome-sequencing [ Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND ]
    Genomic subtyping (e.g., ERG, SPINK1, SPOP, FOXA1, PTEN, circulating nucleic acids (CNA) data...) will be performed based on exome-sequencing data. The exome and CNA data will be linked with the transcriptome data on androgen regulation and DNA repair pathways.

  8. PSA kinetics [ Time Frame: Up to 40 months ]
    Changes of PSA during time and comparison of PSA values and changes between arms.

  9. Testosterone kinetics [ Time Frame: Up to 40 months ]
    Comparison of total and free serum testosterone and testosterone change between arms

  10. PSA nadir </=0.3ng/ml after neoadjuvant treatment [ Time Frame: After 12 weeks of neoadjuvant therapy before RP + PLND ]

    Differences in proportions of PSA nadir </=0.3ng/ml after neoadjuvant treatment.

    PSA nadir after neoadjuvant therapy and before external beam radiotherapy (EBRT) is an important biomarker of hormonal response and an independent prognostic factor of prostate cancer survival.


  11. Peri-operative features [ Time Frame: up to (about) 5 hours ]
    Differences in peri-operative features (operative time, blood loss, grade of surgical difficulty...) will be collected to evaluate the possible effect of treatment on surgical intervention.

  12. Differences in proportions of surgical complications between arms [ Time Frame: Up to 6 weeks post RP + PLND ]
    Clavien-Dindo classification will be implemented to assess differences in surgical complications between the two arms.

  13. Continence [ Time Frame: Up to 40 months ]
    Assessment of continence rates through validated preoperative and postoperative questionnaire (ICIQ)

  14. Quality of life [ Time Frame: Up to 40 months ]
    Assessment of Quality of life through validated preoperative and postoperative questionnaire (EORTC QLQ-C30)

  15. Erection state [ Time Frame: Up to 40 months ]
    Assessment of erection state through validated preoperative and postoperative questionnaire (IEEF5)

  16. Survival [ Time Frame: Up to 36 months ]
    Three years biochemical recurrence free survival

  17. Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR per arm [ Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND ]
    Standardized Uptake Value (SUV) change (delta) per arm comparing SUV values before and after treatment

  18. Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR between arms [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    SUV delta between the two arms.

  19. Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR and tumour volume [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Correlation between SUV values and the tumour volume (TV) in the RP correspondent volume of interest (VOI) at definitive pathology

  20. Standardized Uptake Value (SUV) on prostate [68]Ga PSMA PET/MR and Immunohistochemistry [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Correlation between SUV values and PSMA expression at Immunohistochemistry

  21. Magnetic resonance (MR) and tumor volume (TV) per arm [ Time Frame: At baseline and after12 weeks of neoadjuvant therapy + RP + PLND ]
    Change of magnetic resonance (MR) tumor volume (TV): Tumor volume (TV) change (delta) per arm comparing TV values before and after treatment

  22. Magnetic resonance (MR) and tumor volume (TV) between arms [ Time Frame: At baseline and after12 weeks of neoadjuvant therapy + RP + PLND ]
    Change of magnetic resonance (MR) tumor volume (TV):TV deltas between the two arms.

  23. PI-RADS between arms at MR [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Proportion of PI-RADS between arms

  24. PI-RADS score and Gleason score [ Time Frame: After 12 weeks of neoadjuvant therapy + RP + PLND ]
    Correlation between PI-RADS score and pathology Gleason score

  25. Down-staging at imaging [ Time Frame: At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND ]
    Proportion of down-staging

  26. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: From patient inclusion until RP + PLND ]
    Frequencies of adverse events (AE), severe adverse events (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  2. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations
  3. Male aged 18 years or older (within 80 years)
  4. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  5. Diagnosis of intermediate (at least 2 of the following factors: cT2b, biopsy GS 7, PSA 10-20ng/ml) or high-risk prostatic adenocarcinoma (clinical stage≥T2c and/or biopsy GS≥8 and/or PSA>20ng/ml), cN0-cN1, cM0.
  6. Patient amenable for open or robotic radical prostatectomy + pelvic lymph node dissection
  7. ECOG performance status: 0-1
  8. Adequate organ function as defined by the following criteria:

    • White blood cells (WBC) ≥ 4.0 x109/L
    • Platelet count ≥ 100 x109/L
    • Hemoglobin ≥9 g/dl
    • Creatinine ≤ 2 x ULN
    • Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normality (ULN)
    • Total serum bilirubin ≤1.5 x ULN.

Exclusion Criteria:

  1. Previous surgical/endoscopic treatments for prostatic disease
  2. Herbal and non-herbal products that in the opinion of the investigator may decrease PSA levels
  3. cM1 disease
  4. Any contraindication for PET or MR investigations
  5. History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)
  6. Medications known to lower the seizure threshold
  7. History of:

    • Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer currently in complete remission) within 5 years prior to randomization
    • Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization
    • Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.
    • Gastrointestinal disorder affecting absorption
  8. Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03080116


Contacts
Layout table for location contacts
Contact: Steven Joniau, MD PhD +32 16 34 66 87 steven.joniau@uzleuven.be
Contact: Lorenzo Tosco, MD +32 16 34 66 87 lorenzo.tosco@uzleuven.be

Locations
Layout table for location information
Belgium
University Hospitals Leuven Recruiting
Leuven, Vlaams-brabant, Belgium, 3000
Contact: Gaëtan Devos, MD       gaetan.devos@uzleuven.be   
Contact: Steven Joniau, Prof. MD       steven.joniau@uzleuven.be   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Layout table for investigator information
Principal Investigator: Steven Joniau UZ Leuven
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT03080116    
Other Study ID Numbers: S58827
2016-002854-19 ( EudraCT Number )
First Posted: March 15, 2017    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Universitaire Ziekenhuizen Leuven:
Randomized
Placebo-controlled
Neoadjuvant
Androgen deprivation
Antiandrogen
Radical Prostatectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases